The majority of women with low-grade EC in this study did not have lymphadenectomy or lymph node sampling, including 92.7% and 77.8% with normal and elevated CA-125 levels, respectively. Preoperative elevated CA-125 is known to be associated with lymph node metastases [3] [4] [5] [6] [7] . Therefore, an elevated preoperative CA-125 in the context of low-grade EC might justify referral to a gynecologic oncologist for comprehensive surgical staging, including lymph node assessment. Preoperative computed tomography scan is insufficiently sensitive to detect occult nodal disease [8, 9] . L1 cell adhesion molecule expression (L1CAM) [10, 11] and p53 mutations or high-copy number alterations according to TCGA [12] are recognized for their association with adverse outcomes in endometrial cancer. It remains to be determined if these biomarkers can tailor treatment. Until then, CA-125 can be obtained on anyone diagnosed with endometrial cancer. Reijnen et al. [2] have demonstrated that CA-125 can identify those with low-grade endometrial cancer who are at high risk of recurrence, including distant metastases.
